Content about clopidogrel

November 29, 2012
Eclipsing off-patent Lipitor, Humira tops Rx sales list

Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


November 27, 2012
Wockhardt receives three FDA approvals

Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

SILVER SPRING, Md. — Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

September 28, 2012
Bi-Lo adds generic Plavix to discount program

Supermarket chain Bi-Lo is adding the generic form of a blood-thinning drug to its generic-discount program.

JACKSONVILLE, Fla. — Supermarket chain Bi-Lo is adding the generic form of a blood-thinning drug to its generic-discount program.

The company announced Friday that patients could buy generic clopidogrel for $4 for a 30-day supply and $10 for a 90-day supply with the chain's Pharmacy Discount Card. The branded version of the drug, which recently became available as a generic, is marketed by Sanofi and Bristol-Myers Squibb.

August 30, 2012
Study: Aspirin regimen could benefit prostate cancer patients

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

DALLAS — Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

August 6, 2012
Winn-Dixie adds generic form of Plavix to generics prescription program

Winn-Dixie announced the generic form of Plavix (clopidogrel) now is available for $4 for 30-day and $10 for 90-day prescriptions as part of the company's prescription savings program.

JACKSONVILLE, Fla. — Winn-Dixie announced the generic form of Plavix (clopidogrel) now is available for $4 for 30-day and $10 for 90-day prescriptions as part of the company's prescription savings program.

Winn-Dixie recently launched a prescription savings program in all of its pharmacies that offers deep discounts on more than 400 generic medications and varied discounts on branded and other generic medication.

May 18, 2012
Dr. Reddy's launches generic version of Plavix

Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

Dr. Reddy's announced Friday the launch of clopidogrel tablets in the 75-mg and 300-mg strengths. The drug is a generic version of Plavix, made by Bristol-Myers Squibb and Sanofi. As one of the first companies to submit a completed regulatory application for the 300 mg strength of the drug, Dr. Reddy's received 180 days of market exclusivity for it.

May 17, 2012
FDA approves generic versions of Plavix

The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

May 16, 2012
Generic Plavix arrives at Walmart, Sam's Club stores

Walmart and Sam's Club will be among the first retailers to offer a generic version of an antiplatelet drug.

BENTONVILLE, Ark. — Walmart and Sam's Club will be among the first retailers to offer a generic version of an antiplatelet drug.

Clopidogrel, the generic version of Plavix, will be available at both banners pharmacies on May 19. The patent for the Bristol-Myers Squibb/Sanofi drug officially expires Thursday.

April 11, 2012
Reports: Humira to become top-selling drug this year

Move over, Lipitor: There's a new top drug on the market, according to published reports.

NEW YORK — Move over, Lipitor: There's a new top drug on the market, according to published reports.

March 9, 2012
Kerr Drug, UNC pharmacy school to collaborate in pharmacogenetic study

A regional retail pharmacy chain and a nearby school of pharmacy will collaborate on a study to evaluate the implementation of a pharmacogenetic program in a community pharmacy setting.

RALEIGH, N.C. — A regional retail pharmacy chain and a nearby school of pharmacy will collaborate on a study to evaluate the implementation of a pharmacogenetic program in a community pharmacy setting.

Kerr Drug announced Friday that it would work with the University of North Carolina Chapel Hill's Eshelman School of Pharmacy to explore the feasibility of a program for Sanofi's and Bristol-Myers Squibb's blood-thinning drug Plavix (clopidogrel bisulfate).

January 20, 2012
Lipitor’s patent loss signals future for other top drugs

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot.

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot. Because it’s the top-selling drug, well, ever — with 2010 sales well in excess of $7 billion in the United States alone — Lipitor’s loss of patent protection on Nov. 30, 2011, didn’t start or end the patent cliff but in many ways symbolized it.


September 28, 2011
Study: Supermarket pharmacies could benefit from drug patent expiries

Supermarket pharmacies could see a slight rise in gross profits next year as branded drugs lose patent protection and go generic, according to a new report by Moody's Investors Service.

NEW YORK — Supermarket pharmacies could see a slight rise in gross profits next year as branded drugs lose patent protection and go generic, according to a new report by Moody's Investors Service.

September 12, 2011
FTC fights increasing patent settlements

The issue of patent settlements, their effect on drug prices and availability, and by extension their legality has been around for a long time and will likely remain an issue for years to come. But according to a report released in May by the Federal Trade Commission, the settlements have been on the rise, increasing from 16 in 2009 to 31 in 2010.


The issue of patent settlements, their effect on drug prices and availability, and by extension their legality has been around for a long time and will likely remain an issue for years to come. But according to a report released in May by the Federal Trade Commission, the settlements have been on the rise, increasing from 16 in 2009 to 31 in 2010.


August 16, 2011
Study: Effient reduces cardiovascular risk among younger, heavier patient cohort

A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.

INDIANAPOLIS — A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.

July 21, 2011
Brilinta receives FDA approval

The Food and Drug Administration has approved a drug made by AstraZeneca to reduce the rate of heart attacks in patients with acute coronary syndrome, the Anglo-Swedish drug maker said.

WILMINGTON, Del. — The Food and Drug Administration has approved a drug made by AstraZeneca to reduce the rate of heart attacks in patients with acute coronary syndrome, the Anglo-Swedish drug maker said.

AstraZeneca announced the approval of Brilinta (ticagrelor), a blood-thinning drug, on Wednesday. The drug maker is touting the drug as an alternative to Plavix (clopidogrel), made by Sanofi and Bristol-Myers Squibb.

April 18, 2011
Study: Drug-drug interaction warning letters work

A letter educating healthcare providers regarding a drug-drug interaction between prescription anticlotting drug Plavix (clopidogrel) and a proton-pump inhibitor has resulted in a reduction in the number of patients combining the two therapies, according to a new study by Prime Therapeutics released Monday.

ST. PAUL, Minn. — A letter educating healthcare providers regarding a drug-drug interaction between prescription anticlotting drug Plavix (clopidogrel) and a proton-pump inhibitor has resulted in a reduction in the number of patients combining the two therapies, according to a new study by Prime Therapeutics released Monday.

April 5, 2011
Takeda: Dexilant, Prevacid have less inhibiting effects on Plavix's efficacy than counterparts

Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

NEW ORLEANS — Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

February 18, 2011
As innovaters prep for patent cliff, generics prosper from patent losses

A whole slew of drugs will lose patent protection this year, opening up opportunities for generic drug makers to market their own versions. Most notable among these is Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin), the world’s top-selling drug, with U.S. sales of $7 billion during the 12 months ended September 2010, according to IMS Health.


February 10, 2011
Credit Suisse bullish on supermarket pharmacy

This year’s upcoming $29 billion wave of margin-friendly generic pharmaceuticals will be as big a growth catalyst for supermarket pharmacies as it will be for their pureplay drug store cousins, Credit Suisse research analyst Ed Kelly stated in a note published Thursday.

NEW YORK — This year’s upcoming $29 billion wave of margin-friendly generic pharmaceuticals will be as big a growth catalyst for supermarket pharmacies as it will be for their pureplay drug store cousins, Credit Suisse research analyst Ed Kelly stated in a note published Thursday.

Conservative projection models place the generic impact at 3% to 5% accretive to 2012 earnings, he reported, given that the channel fills between 10% and 15% of all retail prescriptions.

October 6, 2010
IMS Health projects growth for Rx market

The global pharmaceutical market will reach a value of $880 billion next year, according to...

NORWALK, Conn. The global pharmaceutical market will reach a value of $880 billion next year, according to a report by market research firm IMS Health.

 

IMS Health forecasted 5% to 7% growth in 2011 in its annual IMS Market Prognosis, compared with 4% to 5% growth this year.

 

 

March 29, 2010
Plavix patent upheld by U.S. Patent and Trademark Office

The U.S. Patent and Trademark Office plans to uphold the patent protection of a blockbuster...

March 11, 2010
FDA adds boxed warning to Plavix

A popular drug for preventing blood clots may be less effective when taken by a...

March 3, 2010
Bristol-Myers Squibb discusses pipeline with investors

Aims of becoming a leader in biotechnology headlined a meeting Thursday between Bristol-Myers Squibb and...

February 11, 2010
Investors should remember the patent cliff

Some investors quoted in published reports foresee huge gains for such retail pharmacy chains as...

WHAT IT MEANS AND WHY ITS IMPORTANT Some investors quoted in published reports foresee huge gains for such retail pharmacy chains as CVS and Walgreens, as blockbuster drugs like Pfizer’s Lipitor (atorvastatin) and Sanofi-Aventis’ and Bristol-Myers Squibb’s Plavix (clopidogrel bisulfate) come off patent and face generic competition, but they would do well to remember an important factor: the patent cliff.

February 7, 2010
Report: Drug stores may benefit from patent expiries

Patent expiries on blockbuster branded drugs could mean huge profits for some retail pharmacy chains,...